Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 - MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

This is a groundbreaking step toward advancing public health by using more effective and human-relevant methods instead of animal testing The FDA announced that is going to be replacing animal testing ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

Researchers from the Kitasato University in Japan worked with Kao and biotech startup Epsilon Molecular Engineering to develop an antibody candidate they call VHH, per Nikkei. VHH is apparently ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 health care workers in Catalonia who were followed for three years.

State Key Laboratory of Medical Proteomics, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China University of Chinese Academy of Sciences, Beijing 101408, China ...

“Many of the most promising new therapies are antibodies, which cannot efficiently reach the brain without a shuttle to get them across the [blood brain barrier],” Austin added. “This ...